This hierarchical relationship positions G-CIMP as a global epigenetic driver and MGMT methylation as a therapeutically consequential downstream effector, collectively contributing to the favorable prognosis of IDH-mutant gliomas. Here, IDH2 is linked to central nervous system cancer.